Today, the standard therapy for locally advanced or metastatic HR+/HER2- breast cancer is a combination of cyclin-D-dependent kinase 4 and 6 (CDK4/6) inhibitors with endocrine therapy because of better overall and progression-free survival [3,4,5]. The gene discussed is ERBB2; the disease is breast cancer.